Startup profile · funding coverage
Prevision Medicine funding, valuation and investors
Swiss precision-oncology startup that raised $5.4 million in seed funding to commercialize its functional testing platform.
Keep track of Prevision Medicine
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
$5.4M · September 24, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$5.4M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · Zürich, Switzerland
Investors in latest funding
Lead: ACE Ventures
Other: GoHub Ventures , SICTIC
Overview
Prevision Medicine develops functional precision medicine testing for hematological malignancies and solid tumors. On September 24, 2026 it announced a $5.4 million seed round led by ACE Ventures, with GoHub Ventures, SICTIC and angel investors participating.
Why Prevision Medicine is interesting
Primary-source financing and a concrete oncology diagnostic workflow make this a clean healthcare entity record.
Key facts
- Sep 24, 2026: $5.4M seed led by ACE Ventures
Funding history (newest first)
Seed
2026-09-24 $5.4M- ACE Ventures (lead)
- GoHub Ventures (participant)
- SICTIC (participant)
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.